"Help stop" is just . . . the rate goes down at all and we attribute it to GLP-1 agonists? This seems poorly defined.

I assume this resolves positively based entirely on obesity rates in the US, is that correct? I guess if GLP-1 Agonists are entirely pulled from the market it will resolve negatively regardless of obesity rates?

Obesity rates have already been falling in children, teens, and very young adults iirc. We're already past an inflection point.

@jeremiahsamroo Source? I have not heard this.